Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
60 hedge funds and large institutions have $9.86M invested in Acorda Therapeutics in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 28 reducing their positions, and 23 closing their positions.
24% less funds holding
Funds holding: 79 → 60 (-19)
44% less capital invested
Capital invested by funds: $17.6M → $9.86M (-$7.75M)
64% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 28
83% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 23
87% less call options, than puts
Call options by funds: $103K | Put options by funds: $793K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Parallax Volatility Advisers
San Francisco,
California
|
+$894K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$468K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$388K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$80.3K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$72.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$925K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$720K |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$706K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$464K |
| 5 |
Millennium Management
New York
|
-$389K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MIH
76
Meitav Investment House
Bene-Beraq,
Israel
| – | -$7K | -83 | Closed |
|
|
PCM
77
Prelude Capital Management
New York
| – | -$5K | -53 | Closed |
|
78
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$3K | -26 | Closed |
|
|
WEC
79
Winslow Evans & Crocker
Boston,
Massachusetts
| – | -$1K | -8 | Closed |
|
ACOR Hedge Fund Activity: Q3 2020 in Review
60 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q3 2020, worth a combined $9.86M — down 44% from $17.6M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ACOR and 4 opened new positions — a net loss of 19 holders — while 28 trimmed existing stakes and 10 added.
The largest buyer was Parallax Volatility Advisers, adding an estimated $894K. The largest seller was Dimensional Fund Advisors, cutting an estimated $925K.
- 60 institutional investors held Acorda Therapeutics (ACOR) as of Q3 2020, down from 79 in Q2 2020.
- Funds reported $9.86M of Acorda Therapeutics stock for Q3 2020, down 44% quarter-over-quarter.
- 4 funds opened new Acorda Therapeutics positions in Q3 2020 and 23 closed out, a net change of -19 holders.
- The largest Acorda Therapeutics buyer in Q3 2020 was Parallax Volatility Advisers, an estimated $894K added.
- The largest Acorda Therapeutics seller in Q3 2020 was Dimensional Fund Advisors, an estimated $925K sold.
Based on aggregated 13F filings for Q3 2020.